GSM gold starGSM Global
中文版 · Chinese

FDA Approves Giredestrant in Combination With Everolimus for ESR1-Mutated Advanced Breast Cancer

Monday, November 16, 2026 · Federal · GSM News

On November 16, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly, Genentech, Inc.) in combination with everolimus for the treatment of adults with a defined type of locally advanced or metastatic breast cancer.

According to the FDA approval notice, eligible patients must have estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated disease, as detected by an FDA-authorized test, and their disease must have recurred during or after completion of endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting. Giredestrant is an oral estrogen receptor antagonist, and the approval covers its use in combination with everolimus.

The approval was listed in the FDA's oncology and hematologic malignancies approval notifications dated November 16. (Source: U.S. Food and Drug Administration)

Source: U.S. Food and Drug Administration

Published by GSM · USA (original Chinese edition)

Photo: 图:美国食品药品监管局(FDA)总部大楼入口(门楣标示 FOOD AND DRUG ADMINISTRATION)。FDA 官方图,公共领域,经 Wikimedia Commons,本站联邦图库固定图、本篇裁切变体。 / Photo: Entrance of U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons; GSM federal asset library, cropped variant for this story.

Latest in Federal